Showing posts with label medtronic aneurx stent. Show all posts
Showing posts with label medtronic aneurx stent. Show all posts

Thursday, March 20, 2008

U.S. Food & Drug Administration (FDA) Daily Digest Bulletin

Update: 1


Subject: CDRH New Update

Skip NavigationFDA Logo links to FDA home pageCenter for Devices and Radiological Health, U.S. Food and Drug AdministrationHHS Logo links to Department of Health and Human Services website

FDA Home Page | CDRH Home Page | Search | A-Z Index U.S. Food and Drug AdministrationCenter for Devices and Radiological Health Questions?
horizonal rule
CDRHNEW Logo Date: March 19, 2008

The following new items were added to the CDRH web pages on March 18, 2008. Previous CDRH New Items can be found on the CDRHNew Page.

* FDA Public Health Notification: Updated Data on Mortality Associated with the Medtronic AneuRx® Stent Graft System Text
* Medical Devices Dispute Resolution Panel Advisory Meeting, April 19, 2007 - Minutes Text

---


Update : 2

Subject: Enforcement Report for March 19, 2008

Enforcement Report for March 19, 2008
Wed, 19 Mar 2008 07:17:00 -0500

Weekly report by the Food and Drug Administration, Department of Health and Human Services. It contains information on actions taken in connection with agency Regulatory activities.


Update : 3

Subject: FDA Warning Letters Update

You are subscribed to FDA Warning Letters for U.S. Food & Drug Administration (FDA). This information has recently been updated, and is now available.


Update : 4

Subject: Mortality Data Associated with the AneuRx® Stent Graft System - Medical Device Safety Update

Healthcare providers should be aware of a new public health notification that re-emphasizes the need for continued surveillance of patients treated with endovascular grafts and to provide updated information on the mortality risks associated with the use of the Medtronic AneuRx® Stent Graft System.


Update : 5

Subject: FDA Data Standards Update - Additional Section Headings' LOINC Codes & Names

Greetings,

The FDA Data Standards Council's website was updated Wednesday, March 19, 2008, to include eight new LOINC codes and names for section headings.

51941-3 - PACKAGE LABEL.BACK PANEL

51947-0 - PACKAGE LABEL.BOTTOM PANEL

51948-8 - PACKAGE LABEL.FLAP PANEL

51945-4 - PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

51944-7 - PACKAGE LABEL.SIDE PANEL

51943-9 - PACKAGE LABEL.SIDE PANEL.LEFT

51942-1 - PACKAGE LABEL.SIDE PANEL.RIGHT
51946-2 - PACKAGE LABEL.TOP PANEL

Here is the hyperlink to the web page with the new LOINC codes and names: http://www.fda.gov/oc/datacouncil/loinc.html

Lonnie Smith

Project Manager

Food and Drug Administration


Update : 6

Subject: Food For Life Baking Co., Inc. Recalls Spelt Bread (March 18)

Food For Life Baking Co., Inc. Recalls Spelt Bread (March 18)
Wed, 19 Mar 2008 10:18:00 -0500

Food For Life Baking Company of Corona, California is voluntarily recalling 2,241 cases of Spelt Bread (UPC# 07347200168) because they contain spelt grain which is known to be a hybrid of wheat. People who have allergies to wheat or those with Celiac Disease may run the risk of a serious or life threatening allergic reaction if they consume spelt products.


Update : 7

Subject: Williams Foods, Inc. Issues Allergy Alert on Undeclared Milk in Bass Pro Shops Uncle Buck's Light 'N Krispy Fish Batter Mixes (March 18)

Williams Foods, Inc. Issues Allergy Alert on Undeclared Milk in Bass Pro Shops Uncle Buck's Light 'N Krispy Fish Batter Mixes (March 18)
Wed, 19 Mar 2008 13:12:00 -0500

The product is sold in Bass Pro Shops Uncle Buck's labeled 22 ounce canisters and 8 ounce flexible pouches. This recall applies to the following lot numbers: 31207A11, 35107A11, 06308A11 (22 ounce canisters) and 3530716 (8 ounce pouches). Only the "Light 'n Krispy" version of the Bass Pro Shop's Uncle Buck's Fish Batter Mixes are affected by this recall.


Update : 8

Subject: FDA Approves New Medical Adhesive to Treat Burn Patients

FDA Approves New Medical Adhesive to Treat Burn Patients
Wed, 19 Mar 2008 16:01:00 -0500

The U.S. Food and Drug Administration today approved a new medical adhesive (a fibrin sealant) called Artiss for use in attaching skin grafts onto burn patients.



This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420

Wednesday, March 19, 2008

U.S. Food & Drug Administration (FDA) Daily Digest Bulletin

Update : 1

Subject: Public Health Notifications Update

The FDA has posted a new Public Health Notification providing updated data on Mortality Associated with the Medtronic AneuRx Stent Graft System.

This Notification is available by clicking here.


Update : 2

Subject: Drug Safety Newsletter Update

FDA releases its second issue of the FDA Drug Safety Newsletter at http://www.fda.gov/cder/dsn/2008_winter/toc.htm.


Update : 3

Subject: Getting Up to Date on Glucose Meters

Getting Up to Date on Glucose Meters
Tue, 18 Mar 2008 13:12:00 -0500

FDA is reminding consumers to only use the test strips that are recommended for use with their glucose meter.



Update : 5

Subject: MedWatch - Medtronic AneuRx Stent Graft System: Updated information on mortality risks

MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program

FDA issued a Public Health Notification to inform healthcare professionals of an update to earlier FDA safety information on this product. The notification re-emphasizes the need for continued surveillance of patients treated with endovascular grafts, and provides updated information on the mortality risks associated with the use of the AneuRx Stent Graft System to prevent abdominal aortic aneurysm rupture.

Read the complete MedWatch 2008 safety summary, including a link to the Public Health Notification and previous MedWatch alerts, at:
http://www.fda.gov/medwatch/safety/2008/safety08.htm#AneuRx


Update : 6
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Tue, 18 Mar 2008 12:47:29 -0500 (CDT)
Subject: MedWatch - FDA Drug Safety Newsletter: new online issue available

MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program

The new quarterly issue of FDA's online Drug Safety Newsletter [DSN] has been published today. DSN highlights safety issues related to FDA-approved drug products, based on an assessment of the importance and timeliness of these issues to patient care and the seriousness of the adverse events. The current issue includes an article on 'Pharmacogenomics and Drug Safety" and postmarket safety reviews of Exenatide/acute pancreatitis, PDE5 inhibitors/sudden hearing loss, and TNF-alpha antagonists/serious skin reactions.

The entire online newsletter can be found at http://www.fda.gov/cder/dsn/2008_winter/toc.htm

.


Update : 7

Subject: MedWatch - Tiotropium (marketed as Spiriva HandiHaler): ongoing safety review - possible increased risk of stroke

MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program

Boehringer Ingelheim and FDA notified healthcare professionals that ongoing safety monitoring has identified a possible increased risk of stroke in patients who take Spiriva. This product contains tiotropium bromide and is used to treat bronchospasm associated with chronic obstructive pulmonary disease. Boehringer Ingelheim reported to the FDA that it has conducted an analysis of the safety data from 29 placebo controlled clinical studies (“pooled analysis”). Based on data from these studies, the preliminary estimates of the risk of stroke are 8 patients per 1000 patients treated for one year with Spiriva, and 6 patients per 1000 patients treated for one year with placebo. This means that the estimated excess risk of any type of stroke due to Spiriva is 2 patients for each 1000 patients using Spiriva over a one year period.

It is important to interpret these preliminary results with caution. FDA is working with Boehringer Ingelheim to further evaluate the potential association between Spiriva and stroke. FDA has not confirmed these analyses and while pooled analyses can provide early information about potential safety issues, these analyses have inherent limitations and uncertainty that require further investigation using other data sources. Patients should not stop taking Spiriva HandiHaler before talking to their doctor, if they have questions about this new information. This early communication is in keeping with FDA’s commitment to inform the public about its ongoing safety reviews of drugs.

Read the complete MedWatch 2008 safety summary, including a link to the Early Communication, at:
http://www.fda.gov/medwatch/safety/2008/safety08.htm#Tiotropium



This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420